Renaissance Technologies LLC Buys 513,187 Shares of Aldeyra Therapeutics, Inc. $ALDX

Renaissance Technologies LLC lifted its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 146.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 863,187 shares of the biotechnology company’s stock after acquiring an additional 513,187 shares during the period. Renaissance Technologies LLC’s holdings in Aldeyra Therapeutics were worth $1,459,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Abel Hall LLC bought a new stake in Aldeyra Therapeutics in the first quarter valued at approximately $26,000. Krilogy Financial LLC acquired a new stake in Aldeyra Therapeutics in the first quarter worth $26,000. Chicago Partners Investment Group LLC bought a new position in shares of Aldeyra Therapeutics during the first quarter worth $33,000. Caption Management LLC boosted its position in shares of Aldeyra Therapeutics by 110.6% during the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 132,358 shares in the last quarter. Finally, Global Retirement Partners LLC acquired a new position in shares of Aldeyra Therapeutics in the 4th quarter valued at $52,000. Institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Up 0.7%

Shares of ALDX stock opened at $1.52 on Thursday. Aldeyra Therapeutics, Inc. has a 12-month low of $1.07 and a 12-month high of $6.17. The firm has a fifty day moving average of $1.81 and a 200-day moving average of $2.64. The company has a market capitalization of $91.70 million, a price-to-earnings ratio of -3.90 and a beta of 1.21.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). On average, equities analysts expect that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on ALDX. Wall Street Zen upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Insider Transactions at Aldeyra Therapeutics

In other news, CEO Todd C. Brady purchased 250,000 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $1.67 per share, with a total value of $417,500.00. Following the purchase, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at $2,874,567.66. This trade represents a 16.99% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 11.80% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.